论文部分内容阅读
目的:探讨缬沙坦联合通心络胶囊对糖尿病心肌病患者血清肌钙蛋白,SOD及生活质量的影响。方法:收集我院就诊或住院治疗的60例糖尿病心肌病患者,随机分为实验组和对照组,每组30例。对照组患者给予缬沙坦口服治疗,实验组患者在此基础上给予通心络治疗。检测并比较两组患者治疗前后血清cTnI、生活质量、SOD、运动耐量的变化情况。结果:与治疗前相比,两组患者治疗后血清cTnI和生活质量评分均下降,而SOD和运动耐量水平均升高,差异具有统计学意义(P<0.05);与对照组相比,实验组患者治疗后血清cTnI和生活质量评分较低,而SOD和运动耐量水平较高,差异具有统计学意义(P<0.05)。结论:缬沙坦联合通心络胶囊能够降低糖尿病心肌病患者cTnI、生活质量评分,升高其SOD以及运动耐量水平,对临床具有指导意义。
Objective: To investigate the effects of valsartan combined with tongxinluo capsule on serum troponin, SOD and quality of life in patients with diabetic cardiomyopathy. Methods: Sixty patients with diabetic cardiomyopathy who were treated in our hospital or hospitalized were randomly divided into experimental group and control group, with 30 cases in each group. Patients in the control group were treated with valsartan orally, and patients in the experimental group were given Tongxinluo on this basis. The changes of serum cTnI, quality of life, SOD and exercise tolerance before and after treatment were detected and compared between two groups. Results: Compared with those before treatment, the serum cTnI and quality of life scores of both groups decreased and the levels of SOD and exercise tolerance increased after treatment, the difference was statistically significant (P <0.05). Compared with the control group, After treatment, the serum cTnI and quality of life scores were lower, while the levels of SOD and exercise tolerance were higher in the patients with the difference statistically significant (P <0.05). Conclusion: Valsartan combined with Tongxinluo Capsule can reduce cTnI, quality of life score, increase the level of SOD and exercise tolerance in patients with diabetic cardiomyopathy, which is of clinical significance.